Immunotoxin is a novel class of targeted agents in recent years, which is composed of toxin fragment and antibody or cytokine.
2
最新研究表明新的靶向治疗药物SU11248对格列卫耐药的患者有延长生存期的作用。
Recent research shows that a new targeting therapeutic agent, SU11248, can prolong the survival time of the patients with GISTs who were resistant to Gleevec therapy.
3
然而,在临床中,仍有近三成的病人使用了目前国际上最先进的分子靶向治疗药物却没有效果。
However, in clinical practice, there are still Jinsan Cheng patients to use the current world's most advanced molecular targeted therapies have no effect.